Provided herein are magnetically-responsive, photosensitizer based antimicrobial microemulsions and photodynamic nanoplatforms in which a photosensitizer functionally associated with a plurality of superparamagnetic iron oxide nanoparticles are encapsulated. Also provided are methods and processes utilizing the antimicrobial microemulsions and photodynamic nanoplatforms to treat an oral disease, to reduce a microbial population in a pathogenic oral biofilm and to improve the efficacy of a photosensitizer during an antimicrobial photodynamic therapy treatment of an oral disease.

This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same.

Magnetic nanoparticles for use in a magnetic hyperthermia therapeutic treatment, prophylactic treatment or diagnosis method, wherein the magnetic nanoparticles are administered to a body part of an individual and the body part is exposed to a magnetic field oscillating at a high frequency and at a medium and/or low frequency, wherein the high frequency is 1 MHz at the most, the medium frequency is lower than the high frequency, and the low frequency is lower than the high frequency and lower than the medium frequency when it is present.

The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor. In a non-limiting example, the radioactive phospholipid ether metal chelate or radiohalogenated phospholipid ether has the formula: ##STR00001##
wherein R.sub.1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half-life of greater than 6 hours and less than 30 days, or wherein R.sub.1 comprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R.sub.2 is —N.sup.+(CH.sub.3).sub.3.

A measurement system includes a container configured to contain a solvated target molecule and at least one magnetoresistive (MR) sensor device including at least one MR sensor disposed near the container and configured to measure a magnetic field generated by the solvated target molecule, each of the at least one MR sensor including a pin layer having a pinned direction of magnetization, a free layer having a direction of magnetization that varies with an applied magnetic field, and a non-conductive layer separating the pin layer and the free layer.

An implant device includes a polymer tube including an enclosed inner space, and a mixture of a hydrogel and a plurality of nanoparticles within the enclosed inner space. Each of the plurality of nanoparticles includes a shell, payload within the shell, and one or more photothermal agents on a surface of the shell. A wall of the polymer tube includes one or more layers of nanoporous polymer sheets including a plurality of pores. The dimension of the nanoparticles is greater than the dimension of the pores, and the dimension of the payload is smaller than the dimension of the pores.

A nanoparticle includes a metal-based core, a first coating layer substantially covering the metal-based core to generate a coated metal-based core, and a second coating layer at least partially covering the coated metal-based core, wherein the metal-based core comprises at least one transition metal, and wherein the metal-based core comprises the at least one transition metal substantially in a state of zero oxidation.

Disclosed herein is a controlled drug release system of photoresponsive nanocarriers. Also provided are methods of making the nanocarriers. Also provided are method of using the nanocarriers for the treatment of diseases.

The current invention relates to a combination therapy comprising administering the antimitotic agent ABT-751 to a subject and delivering ionizing radiation to the same subject for the treatment of a brain tumor. Provided is for ABT-751 and ionizing radiation for use in such treatments.

Methods of using magnetized elderberry ferment for antioxidation, preventing osteoporosis and/or improving immunity include administering to a subject in need thereof a composition including a magnetized elderberry ferment, wherein the magnetized elderberry ferment is obtained by sequentially fermenting the elderberry extract with yeast, Streptococcus thermophilus, and Acetobacter aceti in a fermenter under magnetized environment.